ABSI Stock Analysis: Buy, Sell, or Hold?
ABSI - Absci Corporation Common Stock
$3.06
-0.09 (-2.86%)
▼
5d:
+6.25%
30d:
+15.04%
90d:
-12.32%
BUY
MODERATE Confidence
Analysis Updated: Apr 2, 2026 12:00 AM ET
Earnings: May 12, 2026
Smart Money Accumulation
ABSI is down 5.8% this week, but smart money is accumulating calls. Top strike: $4 2026-05-15 with 2,614 OI. Call ratio: 69% View Scanner →
Strength: 4.8/10
Get Alerted When ABSI Hits Your Target Price
Join 10,000+ traders who never miss a move
You're in! Check your email to confirm and set your target price.
100% Free
No spam, ever
Unsubscribe anytime
Interactive Price Chart (1 Month)
Loading chart...
Loading historical data...
Bottom Line:
💡 BUY OPPORTUNITY: ABSI shows positive signals but monitor for confirmation. Company currently unprofitable (negative forward earnings). Moderate conviction.
💡 BUY OPPORTUNITY: ABSI shows positive signals but monitor for confirmation. Company currently unprofitable (negative forward earnings). Moderate conviction.
In-depth Analysis How we analyze
Valuation Analysis: ABSI is currently trading at $3.06, which is considered extended relative to its 30-day fair value range of $2.52 to $2.98.
Technical Outlook: Technically, ABSI is in a downtrend. Immediate support is located at $2.71, while resistance sits at $3.29.
Market Sentiment: ABSI has a strong technical setup (75/100), with favorable trendlines, momentum, and price action for short-term traders. Wall Street analysts see significant upside, with an average price target of $8.03 (+162.4%). Combining these factors, the current setup offers a favorable risk/reward ratio for buyers.
Technical Outlook: Technically, ABSI is in a downtrend. Immediate support is located at $2.71, while resistance sits at $3.29.
Market Sentiment: ABSI has a strong technical setup (75/100), with favorable trendlines, momentum, and price action for short-term traders. Wall Street analysts see significant upside, with an average price target of $8.03 (+162.4%). Combining these factors, the current setup offers a favorable risk/reward ratio for buyers.
Quick Decision Summary
Current Position
EXTENDED
Fair Price Range
$2.52 -
$2.98
Company Quality Score
60/100
(HOLD)
Volume Confirmation
HIGH
Confidence Score
63.2%
All Signals
- BEARISH: Price extended above range
- BULLISH: Strong technical setup (75/100)
- BULLISH: High volume confirmation
- BULLISH: Trading 162.4% below Wall St target ($8.03)
Fair Price Analysis
30-Day Fair Range
$2.52 -
$2.98
Current vs Fair Value
EXTENDED
Support & Resistance Levels
Support Level
$2.71
Resistance Level
$3.29
Current Trend
Downtrend
Technical data as of
Apr 2, 2026
Fundamental Context
Forward P/E (Next Year Est.)
-4.88
Wall Street Target
$8.03
(+162.4%)
Revenue Growth (YoY)
-2.3%
Share & Embed Analysis
Last updated: April 04, 2026 5:05 AM ET
Data refreshes hourly during market hours. Next update: 6:05 AM
Data refreshes hourly during market hours. Next update: 6:05 AM
🔥 Top Stocks Breaking Out Now
| Ticker | Score | Recommendation | Change % |
|---|
Technical Signals Check
Is ABSI showing a specific setup today?
Insider Activity (6 Months)
1
Buys
1
Sells
0
Net
NEUTRAL
Recent Transactions
Andreas Busch
BUY
100000 shares
2026-03-12
Sean Mcclain
SELL
26761 shares
2026-02-02
Top Rated Biotechnology Stocks
Top-rated stocks in Biotechnology by analyst ratings.
| Stock | Analyst Consensus | Analyst Target | Tradestie Score |
|---|---|---|---|
|
ALNY
Alnylam Pharmaceuticals … |
STRONG BUY
33 analysts |
$449 | 58 HOLD |
|
DNLI
Denali Therapeutics Inc |
STRONG BUY
19 analysts |
$33 | 46 HOLD |
|
BBIO
BridgeBio Pharma Inc |
STRONG BUY
19 analysts |
$101 | 61 BUY |
|
ASND
Ascendis Pharma AS |
STRONG BUY
16 analysts |
$290 | 53 HOLD |
|
MLTX
MoonLake Immunotherapeut… |
STRONG BUY
16 analysts |
$26 | 53 HOLD |
